BR112022012917A2 - Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópica - Google Patents

Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópica

Info

Publication number
BR112022012917A2
BR112022012917A2 BR112022012917A BR112022012917A BR112022012917A2 BR 112022012917 A2 BR112022012917 A2 BR 112022012917A2 BR 112022012917 A BR112022012917 A BR 112022012917A BR 112022012917 A BR112022012917 A BR 112022012917A BR 112022012917 A2 BR112022012917 A2 BR 112022012917A2
Authority
BR
Brazil
Prior art keywords
treatment
topical composition
disorder
jak
mucosal
Prior art date
Application number
BR112022012917A
Other languages
English (en)
Inventor
Elliott Russell
Hazot Yohan
Winckle Gareth
Margulis Ariel
Original Assignee
Vyne Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vyne Therapeutics Inc filed Critical Vyne Therapeutics Inc
Publication of BR112022012917A2 publication Critical patent/BR112022012917A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIÇÃO TÓPICA, KIT, MÉTODOS PARA TRATAR OU MELHORAR UM DISTÚRBIO DA PELE, DE MUCOSA, DE CAVIDADE CORPORAL, MÉTODO PARA TRATAR UMA CONDIÇÃO RELACIONADA A JAK, MÉTODO PARA TRATAR OU PREVENIR UM DISTÚRBIO DERMATOLÓGICO, E, USO DA COMPOSIÇÃO TÓPICA. A presente invenção se refere a novas formulações tópicas contendo um tofacitinibe e ou uma fingolimode que são úteis para tratar condições dermatológicas, tal como dermatite atópica, psoríase e eczema.
BR112022012917A 2019-12-31 2020-12-31 Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópica BR112022012917A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962955847P 2019-12-31 2019-12-31
US202063066717P 2020-08-17 2020-08-17
US202063086442P 2020-10-01 2020-10-01
US202063086275P 2020-10-01 2020-10-01
PCT/US2020/067612 WO2021138525A1 (en) 2019-12-31 2020-12-31 Topical composition comprising tofacitinib and fingolimod

Publications (1)

Publication Number Publication Date
BR112022012917A2 true BR112022012917A2 (pt) 2022-09-06

Family

ID=74285586

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012917A BR112022012917A2 (pt) 2019-12-31 2020-12-31 Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópica

Country Status (9)

Country Link
US (1) US20230037905A1 (pt)
EP (1) EP4084776A1 (pt)
JP (1) JP2023509441A (pt)
AU (1) AU2020417290A1 (pt)
BR (1) BR112022012917A2 (pt)
CA (1) CA3163530A1 (pt)
IL (1) IL294239A (pt)
TW (1) TW202135825A (pt)
WO (1) WO2021138525A1 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874794A (en) 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment
EP3065717A1 (en) 2013-11-04 2016-09-14 Biopharmx, Inc. Dosage form comprising an active ingredient and a plurality of solid porous microcarriers

Also Published As

Publication number Publication date
JP2023509441A (ja) 2023-03-08
IL294239A (en) 2022-08-01
US20230037905A1 (en) 2023-02-09
CA3163530A1 (en) 2021-07-08
AU2020417290A1 (en) 2022-05-26
EP4084776A1 (en) 2022-11-09
WO2021138525A1 (en) 2021-07-08
TW202135825A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
MX2022001607A (es) Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola.
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
CO6670567A2 (es) Métodos de tratamiento contra el cáncer pancreático
BR112019006113A2 (pt) métodos de tratamento de distúrbios mitocondriais e metabólicos
BR112015001782A2 (pt) método para produzir uma composição para o tratamento de um dente lesionado
MX2020012018A (es) Composiciones para el tratamiento de condiciones de la piel.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
BR112016024621A2 (pt) composições para tratamento bucal
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
CR20220570A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
CL2023000921A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead
MX2019002047A (es) Metodos y composiciones para tratar infecciones fungicas cutaneas.
BR112022003659A2 (pt) Composições e métodos de tratamento de doenças vasculares
ZA202204938B (en) Enhancement and stabilisation of proteolytic activity of proteases
MX2021003527A (es) Tratamiento de baja intensidad de trastornos hematologicos.
BR112018000589A2 (pt) composição de tratamento de cabelo, método para o tratamento de cabelo e utilização de uma composição
BR112022012917A2 (pt) Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópica
CL2019001338A1 (es) Preparación cosmética de viscosidad mejorada para el tratamiento de las fibras queratínicas, proceso para el aumento de la viscosidad de una preparación cosmética, uso de ingredientes modificadores de la viscosidad y método de tratamiento de las fibras queratínicas.
MX2020000681A (es) Tirotricina para usarse en el tratamiento o profilaxis del olor corporal, y preparaciones de la misma.
BR112023021510A2 (pt) Métodos de tratamento de estenoses esofágicas
CO2022002585A2 (es) Composición cosmética tópica, uso de la composición cosmética y máscara para aplicación facial
MX2019000006A (es) Composiciones para el tratamiento de estrias y ulceras de origen isquemico.
MX2022016179A (es) Compuestos y metodos para tratar infecciones fungicas.
CA3155618A1 (en) Treatment of epileptic conditions with gabaa receptor modulators

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]